Free Trial
NASDAQ:LIXT

Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Lixte Biotechnology logo
$2.11
-0.02 (-0.94%)
(As of 10/31/2024 ET)

About Lixte Biotechnology Stock (NASDAQ:LIXT)

Key Stats

Today's Range
$2.08
$2.23
50-Day Range
$1.31
$2.14
52-Week Range
$1.31
$4.42
Volume
275,570 shs
Average Volume
363,289 shs
Market Capitalization
$4.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
29th Percentile Overall Score

LIXT MarketRank™: 

Lixte Biotechnology scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lixte Biotechnology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lixte Biotechnology is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lixte Biotechnology has a P/B Ratio of 9.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lixte Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    1.02% of the float of Lixte Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Lixte Biotechnology has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lixte Biotechnology has recently decreased by 26.51%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lixte Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Lixte Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.02% of the float of Lixte Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Lixte Biotechnology has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lixte Biotechnology has recently decreased by 26.51%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lixte Biotechnology has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lixte Biotechnology this week, compared to 0 articles on an average week.
  • Search Interest

    7 people have searched for LIXT on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Lixte Biotechnology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Lixte Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.10% of the stock of Lixte Biotechnology is held by institutions.

  • Read more about Lixte Biotechnology's insider trading history.
Receive LIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

LIXT Stock News Headlines

Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Headlines

LIXT Stock Analysis - Frequently Asked Questions

Lixte Biotechnology's stock was trading at $2.35 at the start of the year. Since then, LIXT stock has decreased by 10.2% and is now trading at $2.11.
View the best growth stocks for 2024 here
.

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.45) EPS for the quarter.

Lixte Biotechnology shares reverse split on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Lixte Biotechnology (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LIXT
Employees
3
Year Founded
N/A

Profitability

Net Income
$-5,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.22 per share

Miscellaneous

Free Float
1,900,000
Market Cap
$4.75 million
Optionable
Not Optionable
Beta
-0.15
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LIXT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners